These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 10328706)

  • 1. Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer.
    Spitz IM; Chertin B; Lindenberg T; Farkas A
    N Engl J Med; 1999 May; 340(18):1439. PubMed ID: 10328706
    [No Abstract]   [Full Text] [Related]  

  • 2. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversibility of androgen deprivation therapy in patients with prostate cancer.
    Fridmans A; Chertin B; Koulikov D; Lindenberg T; Gelber H; Leiter C; Farkas A; Spitz IM
    J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S; Lawrentschuk N; Grills RJ; Neerhut G
    J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
    Spitz IM; Chertin B; Fridmans A; Farkas A; Belanger A; Hartman H; Labrie F
    Prostate Cancer Prostatic Dis; 2009; 12(1):100-3. PubMed ID: 18574491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Principles of endocrine manipulation in the treatment of prostatic cancer.
    Neumann F
    Prog Clin Biol Res; 1985; 185A():73-98. PubMed ID: 3898136
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer of the prostate. Mechanisms of action of antiandrogens.
    Habenicht UF; Neumann F; el Etreby MF
    Acta Urol Belg; 1991; 59(4):1-10. PubMed ID: 1840231
    [No Abstract]   [Full Text] [Related]  

  • 8. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiation of LHRH monotherapy for prostate cancer.
    Milsted RA
    Prog Clin Biol Res; 1989; 303():69-74. PubMed ID: 2528742
    [No Abstract]   [Full Text] [Related]  

  • 10. Androgen deprivation therapy for prostate cancer.
    Bahnson R
    J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
    [No Abstract]   [Full Text] [Related]  

  • 11. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
    Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
    J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
    Raina R; Pahalajani G; Agarwal A; Zippe C
    Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal treatment of prostate cancer.
    Garnick MB
    N Engl J Med; 1999 Mar; 340(10):812-3. PubMed ID: 10075531
    [No Abstract]   [Full Text] [Related]  

  • 15. Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer.
    Waxman J
    Prog Clin Biol Res; 1989; 303():61-8. PubMed ID: 2528741
    [No Abstract]   [Full Text] [Related]  

  • 16. Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer.
    Habenicht UF; Schröder H; el Etreby MF; Neumann F
    Prog Clin Biol Res; 1988; 260():63-75. PubMed ID: 2966407
    [No Abstract]   [Full Text] [Related]  

  • 17. Monotherapy in advanced prostate cancer: an overview.
    Baltogiannis D; Giannakopoulos X; Charalabopoulos K; Sofikitis N
    Exp Oncol; 2004 Sep; 26(3):185-91. PubMed ID: 15494685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal therapy of prostate cancer.
    Labrie F
    Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
    Schulze H; Senge T
    J Urol; 1990 Oct; 144(4):934-41. PubMed ID: 2144596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.